Acutaas Chemicals Q1 FY27: Pharma-led surge, while battery chemicals begin commercial supply

Acutaaas Chemicals Limited opened FY27 with a sharp step-up in performance. In Q1 FY27, revenue from operations rose to INR 329.7 crore, up 59.1% year on year. Profitability expanded even faster. EBITDA increased to INR 113.1 crore, up 122.1% year on year, and EBITDA margin rose to 34.3% from 24.6% in Q1 FY26. PAT came in at INR 75.0 crore, up 70.4% year on year.

Management attributed the margin expansion to better product mix and operational efficiencies. It also highlighted that the quarter was operationally challenging due to geopolitical tensions in the Gulf, but the company maintained supply continuity through raw material and logistics planning.

Q1 performance: Pharma Intermediates drives the quarter

Acutaaas operates across Pharma Intermediates and Specialty Chemicals. The quarter’s growth was led by the Pharma Intermediates segment.

On the earnings call, management said Advanced Pharmaceutical Intermediates revenue was INR 292.7 crore in Q1 FY27, a year-on-year growth of 76.5%. Within this, it noted strong momentum in CDMO and robust growth in the core advanced intermediates business. The company did not disclose a revenue split between CDMO and non-CDMO.

Specialty Chemicals revenue was INR 37.0 crore, down 10.6% year on year. Management said the BFC business recovered strongly, but this was offset by a decline in commodity chemicals, which is consistent with the company’s plan to phase out lower value products.

The company also reported a sharp drop in other income versus the previous quarter. Management explained that Q4 FY26 benefited from positive euro exchange fluctuation, which did not recur in Q1 FY27.

Specialty Chemicals reset: commodity exit and a transition gap

Specialty Chemicals is going through a portfolio change. Management reiterated that it is gradually phasing out commodity chemicals starting this financial year, and replacing them with newer higher-margin products.

This transition can create a short-term gap. The company acknowledged that even though overall capacity remains largely unchanged, minor capex is required to align plants for the new products. This can result in a timing mismatch between the phase-out of old products and ramp-up of new ones.

Still, management said it does not expect the overall Specialty Chemicals business to decline for the full year. It expects commodity chemical revenue to keep declining over coming quarters, but believes this will be more than offset by growth in BFC, new revenue from battery chemicals, and additional specialty products with better margins.

Battery chemicals: plant validated, commercial supply started

A key strategic highlight was progress in battery chemicals. Management stated that it has successfully completed the trial run of its battery chemicals plant and has started commercial supply.

While it did not quantify battery chemical revenues for Q1, it said production will ramp up quarter-on-quarter from Q2, Q3, and Q4. It also underlined that demand is not the constraint. The constraint is plant capacity, implying that execution and scale-up will be the primary milestones to track.

Management reiterated its prior expectation that the battery chemicals plant should reach full capacity utilization in about three years.

Semiconductor chemicals: Indichem Korea capex nearing completion

The company also discussed the Indichem plant in Korea, which will target semiconductor chemicals. Management said construction is progressing ahead of schedule, and capex completion is expected by the end of the quarter discussed on the call. It expects revenue contribution from the next financial year onwards.

It also said the R and D facility in Korea has already been commissioned and product development has started, which may reduce time to commercialization. However, it did not commit to product-level timelines, and noted that this is a new business likely to start slowly. It expects capacity to ramp over 3 to 4 years.

Guidance and balance sheet signals

For FY27, management reaffirmed two key points.

First, it remains confident of delivering 25% revenue growth for the full year.

Second, it expects full-year margins to be in line with FY26, even though Q1 margins were significantly higher. Management explained that blended margins will depend on mix, especially as newer businesses scale.

On the balance sheet, management stated net cash and cash equivalents were about INR 314 crore as of June 30, 2026. It also said working capital days increased to 99 days versus 91 days in Q4 FY26, driven by higher inventory days despite improvements in debtors and creditors.

It also provided quarterly capacity utilization across sites: Sachin at 83%, Ankleshwar Unit 2 at 23%, and Jhagadia Unit 3 at 55%.

Takeaways

Acutaaas delivered a strong start to FY27, led by Pharma Intermediates and a favorable mix that expanded margins sharply. Specialty Chemicals is in a deliberate portfolio reset, with near-term volatility possible due to commodity exits.

The bigger strategic swing factors now sit in execution. Battery chemicals have moved from trial to commercial supply, and the Indichem Korea project is nearing capex completion, with revenue expected from next year. If these ramp-ups track management’s timelines, the revenue mix could gradually shift away from the historical Pharma-heavy profile, while maintaining a blended margin profile similar to FY26.